Drug Trial Radar · NCT01962909
Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Mar 18, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
3
Actual
Start
Nov 2013
Primary completion
Jan 2016
Study completion Jan 2016
Sponsor
- Lead sponsor
- University of VirginiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 14, 2013
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to study an experimental drug called PTP-01 that is being used as an imaging agent to diagnosis pancreatic cancer. Currently, pancreatic cancer is diagnosed using CT or MRI scans which miss small pancreatic cancers, particularly early stage disease. Researchers at the University of Virginia have identified a biomarker for pancreatic cancer called plectin, which is very specific for pancreatic cancer and not other, non-cancerous conditions involving the pancreas. These researchers have also developed PTP-01, an experimental drug that may be used with SPECT imaging to detect pancreatic cancer cells in humans.
Conditions
- Pancreatic Ductal Adenocarcinoma
Interventions
PTP-01Drug
Dose level 1 is 10mCi (50ug of peptide)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ability of PTP-01 to detect pancreatic ductal adenocarcinomaTime frame: up to 72 hours post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Virginia
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.